相关临床试验
15
0 进行中
药物批准
276
批准总数
监管机构
1
监管机构数
成立时间
N/A
已完成
15
100.0%
- Modicus Prime raised $8 million in total funding, including a recent $4.5 million round led by Frist Cressey Ventures, to expand its AI compliance infrastructure for pharmaceutical companies. - The company's Trustworthy AI Compliance Software integrates with pharmaceutical technology stacks to provide centralized oversight for AI governance across regulated GxP environments globally. - The platform addresses an industry problem estimated at $50 billion annually in quality control failures by enabling audit-ready AI deployment across pharmaceutical organizations. - CEO Taylor Chartier co-authored the ISPE GAMP AI Guide and has been instrumental in shaping industry standards for AI implementation in regulated pharmaceutical environments.
- Asgard Therapeutics has appointed Professor Dr. Wolfram Brugger as Chief Medical Officer to lead the clinical development of AT-108, a first-in-class gene therapy. - AT-108 represents a breakthrough "personalized off-the-shelf" immunotherapy that reprograms tumor cells into dendritic cells to trigger personalized immune responses against cancer. - Dr. Brugger brings extensive experience from over 130 Phase I-III oncology trials and successful drug development programs at AstraZeneca, MorphoSys, and Autolus Therapeutics. - The company is currently advancing IND-enabling studies for AT-108, with key proof-of-concept data published in Science journal in 2024.
- Salarius Pharmaceuticals will rebrand as Decoy Therapeutics Inc. with new NASDAQ ticker "DCOY" effective January 2026, marking a strategic transformation into a platform-driven biotechnology company. - The company is advancing a proprietary peptide-conjugate platform targeting pan-coronavirus activity and multi-viral threats including influenza and RSV, with lead programs attracting interest from BARDA. - Decoy leverages AI and machine learning tools alongside high-speed synthesis techniques to rapidly design peptide conjugate drug candidates for respiratory viruses and gastrointestinal cancers. - The company plans to advance multiple investigational new drug applications in 2026 while pursuing strategic partnerships and non-dilutive funding opportunities.
- Insightec has spun out Lotus Neuro, a clinical-stage biotechnology company focused on advancing brain-targeted therapeutics using precision, low-frequency focused ultrasound technology. - The new company will initially target neuro-oncology programs including glioblastoma and diffuse midline gliomas, while developing partnerships in neurodegeneration. - Lotus Neuro builds on Insightec's proven platform that has treated over 25,000 patients and recently demonstrated improved survival outcomes in glioblastoma trials. - The spin-out is funded by Nexus NeuroTech Ventures and will be led by Dr. Arjun Desai, former Chief Strategic Innovation Officer at Insightec.
- Link Cell Therapies officially launched from stealth mode with a $60 million Series A financing led by Johnson & Johnson Innovation, bringing total funding to $92 million across seed and Series A rounds. - The company's proprietary logic-gating technology enables CAR-T cells to target multiple antigens co-expressed on cancer cells while sparing healthy tissues that express only one target. - Lead program LNK001 for renal cell carcinoma is on track for IND application and Phase I trial initiation in 2026, with a second colorectal cancer program targeting development candidate selection in 2026. - The platform addresses a key limitation of CAR-T therapy in solid tumors by creating "clean" target pairs that minimize on-target, off-tumor toxicity.
- Cambridge-based Cellular Origins closed an oversubscribed $40 million Series A funding round led by Johnson & Johnson Innovation to advance its Constellation robotic automation platform for cell and gene therapy manufacturing. - The company's technology addresses a critical bottleneck in the CGT sector, where current production systems serve fewer than 7% of eligible patients worldwide due to manufacturing limitations. - The funding will support commercial team expansion, platform development, and infrastructure scaling to enable production of hundreds of thousands of therapy doses while maintaining biological performance. - Strategic partnerships with industry leaders including Cytiva, Fresenius Kabi, Thermo Fisher Scientific, and Wilson Wolf validate the platform's commercial potential in addressing manufacturing challenges.
- Salarius Pharmaceuticals and Decoy Therapeutics have completed their strategic merger, creating a combined company focused on advancing peptide conjugate therapeutics through Decoy's proprietary IMP3ACT platform. - The merged entity combines artificial intelligence, machine learning, and high-speed synthesis techniques to rapidly design and manufacture drug candidates targeting respiratory infectious diseases and gastrointestinal oncology. - Decoy plans to file an Investigational New Drug application for its lead pan-coronavirus antiviral within 12 months and advance additional programs including broad-acting antivirals for flu, COVID-19, and RSV. - The combined company has pro forma cash of $14 million following the merger and recent public offering, with the new entity to be renamed Decoy Therapeutics.
• PAQ Therapeutics has raised $39 million in Series B financing co-led by MRL Ventures Fund and Bayland Capital, with participation from several other investors including Johnson & Johnson Innovation. • The company has initiated a Phase 1 clinical trial for PT0253, its lead candidate that selectively degrades KRAS G12D mutations, a known driver for various solid tumors with high unmet medical needs. • Preclinical data suggests PT0253 has best-in-class potential compared to existing agents targeting the same KRAS mutant, potentially offering more effective and durable treatment options for patients with lethal cancers.
- Citryll BV raised €85 million in a Series B funding round co-led by Johnson & Johnson Innovation, Forbion, and Novartis Venture Fund to advance clinical development of CIT-013. - CIT-013, a first-in-class monoclonal antibody, targets Neutrophil Extracellular Traps (NETs) by binding to Histone 2A and Histone 4, addressing the source of autoantigens in immune-mediated disorders. - Phase IIa trials are planned for rheumatoid arthritis (RA) and hidradenitis suppurativa (HS) to establish CIT-013’s dual mechanism of action in clearing existing NETs and inhibiting new NET formation. - The funding will support further clinical studies of CIT-013, which has potential applications across a wide range of immune-mediated inflammatory diseases beyond RA and HS.
• Wales establishes a major life sciences initiative with a £100 million investment fund, representing the largest sector-specific investment in the country's history. • Life Sciences Hub Wales secures Johnson & Johnson Innovation and GE Healthcare as anchor tenants, creating a collaborative ecosystem for academia, business, and healthcare sectors. • The initiative has already invested £20 million in strategic projects, including Simbec Research's expansion and ReNeuron's relocation of cell manufacturing operations to Wales.
